AndrewMatthewFarlandMD
Oncology • Winston Salem, NCAssistant Professor, Internal Medicine, Bowman Gray School of Medicine of Wake Forest Univ
Dr. Farland is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
S Hawthorne Rd
Winston Salem, NC 27157Phone+1 336-716-3182Fax+1 336-713-5424
Education & Training
Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012- Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 2006 - 2009
Virginia Commonwealth University School of MedicineClass of 2006
Certifications & Licensure
NC State Medical License 2006 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012
Publications & Presentations
PubMed
- Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era.Ayotola Fatola, Michael D Evans, Jenna Brown, Elizabeth Davis, Andrew Johnson
Blood Advances. 2025-01-28 - A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura.Mouhamed Yazan Abou-Ismail, Chong Zhang, Angela P Presson, Shruti Chaturvedi, Ana G Antun
Research and Practice in Thrombosis and Haemostasis. 2024-03-01 - 2 citationsA descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry.Mouhamed Yazan Abou-Ismail, Chong Zhang, Angela P Presson, Shruti Chaturvedi, Ana G Antun
Blood Advances. 2024-02-13
Abstracts/Posters
- Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian PopulationsAndrew M. Farland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic PurpuraAndrew M. Farland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
